Luna Awarded NIH Grant to Apply Nanotechnology to Allergy Treatment
22 Julho 2008 - 9:30AM
Business Wire
Luna Innovations Incorporated (NASDAQ:LUNA) announces the award of
a $1.6 million Research Project Grant (R01) from the National
Institutes of Health (NIH) to investigate the use of
fullerene-based nanomedicines as a pathway to treat allergies and
other inflammatory diseases. This novel research program may offer
a new therapeutic solution using fullerene compounds for treating
allergies and other conditions that play a central role in
inflammatory reactions, such as arthritis and multiple sclerosis.
The study will include evaluating Luna�s exclusive nanomedicine
prototypes. Allergic conditions and other autoimmune diseases
affect millions of people worldwide. These diseases are induced in
tissues that contain mast cells (cells that line the surfaces of
the skin, mouth, nose, eyes, sinuses, and lungs) and basophils
(cells that are in the blood stream). Both cells contain histamine,
the main cause of inflammatory allergic diseases. Fullerenes are a
novel class of carbon molecules that have unusual biological
properties due to their unique structure. Luna�s team of scientists
in Danville, Virginia are synthesizing a variety of fullerenes to
develop new or improved technologies to diagnose, monitor, and
treat certain medical conditions. �Our fullerenes are spherical
carbon nanomaterials that have been modified to target sites within
cells that amplify the immune response,� explained Dr. Chris
Kepley, Principal Investigator of the RO1 and nanoImmunology Group
Leader at Luna. �We have discovered that our fullerene prototypes
block the noxious effects of allergies and therefore may be a new
way to control allergies and other diseases that are largely due to
mast cell and basophil responses. Because these nanomedicine
prototypes appear to work through a unique pathway, it is possible
they could combine with existing medicines and produce a synergy,
which makes a significant impact on these diseases.� In this
program under the NIH�s National Institute of General Medical
Sciences, Luna will explore whether fullerenes control allergies by
investigating the systemic, cellular and molecular responses in
vivo and in vitro. An interdisciplinary research team, led by Dr.
Kepley, has been assembled to accomplish these studies. This team
combines expertise in the chemical, physical and biological
sciences and state-of-the-art methodologies and models. About Luna
Innovations: Luna Innovations Incorporated
(www.lunainnovations.com) develops and manufactures new-generation
products for the healthcare, telecommunications, energy and defense
markets. Luna�s products are used to measure, monitor, protect and
improve critical processes in the markets we serve. Luna nanoWorks
(www.lunananoworks.com) is a division of Luna Innovations. With a
world-class nanomaterial manufacturing facility in Danville,
Virginia, the nanoWorks Division is developing products empowered
by nanomaterials with applications in diagnostics and therapeutics.
Through its disciplined commercialization business model, Luna has
become a recognized leader in transitioning science to solutions.
The Company is headquartered in Roanoke, Virginia. Forward Looking
Statements: This release includes information that constitutes
�forward-looking statements� made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995,
including statements regarding, but not limited to: Luna�s
fullerene-based nanomedicine prototypes� ability to offer new
therapeutic solutions for treating allergies and other medical
conditions, and Luna�s ability to develop new and/or improved
technologies to diagnose, monitor or treat medical conditions. The
company attempts, whenever possible, to identify forward-looking
statements by words such as �intends,� �will,� �plans,�
�anticipates,� �expects,� �may,� �estimates,� �believes,� �should,�
�projects,� or �continue,� or the negative of those words or
comparable words. Factors that could cause actual results to differ
materially from the expectations expressed in such forward-looking
statements include, but are not limited to: the safety of
nanomedicine prototypes, whether real or perceived, the potential
limitations of regulatory requirements in obtaining clearance by
the U.S. Food and Drug Administration or other regulatory agencies
for the company�s products and the timeline for bringing any new
drugs based on nanomaterials to market. Statements that describe
the Company�s business strategy, goals, prospects, opportunities,
outlook, plans or intentions are also forward looking statements.
Actual results may differ materially from the expectations
expressed in such forward-looking statements as a result of various
factors, including risks and uncertainties set forth in the
company�s periodic reports and other filings with the Securities
and Exchange Commission. Such filings are available at the SEC�s
website at http://www.sec.gov, and at the company�s website at
http://www.lunainnovations.com. The statements made in this release
are based on information available to the company as of the date of
this release and Luna Innovations undertakes no obligation to
update any of the forward-looking statements after the date of this
release.
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024